Search

Home > New FDA Approvals > 126 - NDA for ALKS5461; clearance for cobas® CT/NG for cobas® 6800/8800 Systems; FDA cracks down on dietary supplements with caffeine
Podcast: New FDA Approvals
Episode:

126 - NDA for ALKS5461; clearance for cobas® CT/NG for cobas® 6800/8800 Systems; FDA cracks down on dietary supplements with caffeine
Category: Science & Medicine
Duration: 00:09:26
Publish Date: 2018-04-16 07:00:00
Description:

April 16, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 

1:26 Alkermes announces FDA acceptance for review of New Drug Application for ALKS5461 for the adjunctive treatment of major depressive disorder https://www.prnewswire.com/news-releases/alkermes-announces-fda-acceptance-for-review-of-new-drug-application-for-alks-5461-for-the-adjunctive-treatment-of-major-depressive-disorder-300630031.html

3:20 Roche receives FDA clearance for cobas® CT/NG for cobas® 6800/8800 Systems https://www.prnewswire.com/news-releases/roche-receives-fda-clearance-for-cobas-ctng-for-cobas-68008800-systems-300629816.html 

5:23 FDA takes step to protect consumers against dietary supplements containing dangerously high levels of extremely concentrated or pure caffeine https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604485.htm 

Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com. 

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0